2型糖尿病患者门诊使用口服降糖药联合GLP-1受体激动剂转换为德谷胰岛素利拉鲁肽注射液的案例分享  

Case Sharing of Oral Hypoglycemic Drugs Combined with GLP-1 Receptor Agonists Converted to Insulin Degludec and Liraglutide Injection in Outpatients with Type 2 Diabetes

作　　者：于俊杰[1] 马建华[2] YU Junjie;MA Jianhua(The 2nd Affiliated Hospital Of Harbin Medical University,Harbin Heilongjiang 150001,China;Nanjing First Hospital,Nanjing Jiangsu 210006,China.)

机构地区：[1]哈尔滨医科大学附属第二医院,黑龙江哈尔滨150001 [2]南京市第一医院,江苏南京210006

出　　处：《药品评价》2022年第13期819-822,共4页Drug Evaluation

摘　　要：回顾性总结5例门诊口服降糖药联合GLP-1受体激动剂(GLP-1RA)治疗控制不佳,转换为德谷胰岛素利拉鲁肽注射液联合二甲双胍和(或)钠?葡萄糖共转运蛋白2(SGLT2)抑制剂的成人2型糖尿病(T2DM)患者病例资料。随访发现,治疗1个月后患者空腹和餐后血糖均有明显改善,3个月时体重、腰围有一定程度的下降,均未出现低血糖发生和胃肠道不良反应,临床有效性和耐受性良好。Retrospective review clinical data of 5 adult type 2 diabetic patients uncontrolled by oral antidiabetic drugs combined with GLP-1 receptor agonists in outpatient.After 1 month,both fasting and postprandial glucose improved after converting to insulin degludec and liraglutide (IDegLira) injection combined metformin with or without SGLT2 inhibitor.After 3 months,body weight loss and abdominal circumference loss were seen in most patients,that no hypoglycemia and gastrointestinal adverse events.In general,insulin degludec and liraglutide injection was effective and well-tolerated.

关 键 词：糖尿病 2型 德谷胰岛素利拉鲁肽注射液 口服降糖药 GLP-1受体激动剂 门诊 

分 类 号：R587.1[医药卫生—内分泌]